StockWatch
·
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Quarterly ResultAug 5, 2026, 04:04 PM

Alpha Teknova Q2 Revenue $12.2M, Raises 2026 Guidance to $45-47M

AI Summary

Alpha Teknova, Inc. announced strong financial results for the second quarter ended June 30, 2026, with total revenue reaching a record $12.2 million, an 18% increase over the prior year. Following these results, the company raised its full-year 2026 revenue guidance to $45-47 million and improved its Free Cash Outflow outlook to less than $8 million. Additionally, Teknova launched its new AI-powered Build-Tek™ custom order configurator, aiming to accelerate the path from preclinical to clinical manufacturing.

Key Highlights

  • Q2 2026 total revenue was $12.2 million, up 18% year-over-year.
  • Company raised 2026 revenue guidance to $45-47 million.
  • Improved 2026 Free Cash Outflow outlook to less than $8 million.
  • Launched proprietary AI-powered Build-Tek™ custom order configurator.
  • Q2 2026 gross profit was $4.9 million, with a gross margin of 40.1%.
  • Q2 2026 net loss was $3.2 million, or negative $0.06 per diluted share.
  • Total cash and short-term investments were $17.4 million at quarter-end.